Sonrotoclax Tablets 1 mg, 5 mg, 20 mg, 80 mg Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 1 mg, 5 mg, 20 mg, 80 mg
Reference Brands: Beqalzi
Category: Oncology Cancer Care
Sonrotoclax (Beqalzi, BeOne Medicines) is a next-generation BCL2 inhibitor tablet. The US FDA approved it in May 2026 for relapsed or refractory mantle cell lymphoma, after a conditional approval in China. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers, API makers and licensees preparing for patent expiry.
Manufacture or export Sonrotoclax Tablets? List it or send an offer →
Product Description:
Sonrotoclax blocks BCL2, a protein that keeps cancer cells alive by switching off their built-in self-destruct pathway (apoptosis). It works in the same way as venetoclax but binds BCL2 more tightly and is cleared from the body faster, which allows shorter dose ramp-up and use in combinations.
The US FDA granted sonrotoclax accelerated approval as Beqalzi in May 2026 for adults with relapsed or refractory mantle cell lymphoma after at least two lines of therapy, including a BTK inhibitor. China gave it conditional approval earlier in 2026. BeOne Medicines (formerly BeiGene) is also developing it with its BTK inhibitor zanubrutinib in chronic lymphocytic leukaemia. Doses are built up gradually using 1, 5, 20 and 80 mg tablets to lower the risk of tumour lysis syndrome.
Sourcing and licensing notes. Sonrotoclax is patented and made only by BeOne; there is no generic. We handle authorised-supply enquiries and connect developers and licensees interested in the molecule ahead of patent expiry.
How Sonrotoclax Tablets is supplied today, and licensing ahead of patent expiry
Where sonrotoclax is approved
Checked 3 Oct 2026| Market | Status | Brand · regulator · date |
|---|---|---|
| China | Approved | NMPA · conditional approval · early 2026 |
| United States | Approved | Beqalzi · FDA · May 2026 (accelerated) |
| Generic / biosimilar | None | None approved as of the check date |
Not approved in your country? A hospital or doctor can often still import it for a named patient, through a special-access, import-permit or compassionate-use route. We confirm which route applies in your country and the documents needed before quoting. Ask about named-patient supply →
Frequently Asked Questions
Relapsed or refractory mantle cell lymphoma after at least two prior treatments, including a BTK inhibitor.
Beqalzi, from BeOne Medicines (formerly BeiGene). The US FDA approved it in May 2026.
Both block BCL2. Sonrotoclax binds more tightly and is cleared faster, which is intended to make dosing and combinations easier.
No. It is patented. We handle authorised-supply enquiries and connect developers and licensees preparing for patent expiry.
Related Products
Relacorilant Capsules
Strength:
25 mg, 100 mg
Form: Soft capsules
Reference Brands: Lifyorli
View Details
Larotrectinib Sulfate
Strength:
25 mg, 100 mg, 20 mg/mL
Form: Capsule / Oral suspension
Reference Brands: Vitrakvi (USA/EU/LATAM)
View Details
Pertuzumab
Strength:
420 mg/14 mL
Form: Solution for IV infusion
Reference Brands: Perjeta (USA/EU)
View Details
Sacituzumab Govitecan
Strength:
180 mg
Form: Injection
Reference Brands: Trodelvy (USA/EU)
View DetailsUsually answered within 48 hours | GMP documents shared before you commit
